Endotec Calls FDA’s AIP Decision “Extreme,” Probes Appeal Mechanisms
This article was originally published in The Gray Sheet
Executive Summary
Endotec is asking CDRH Ombudsman Les Weinstein to assist in obtaining a formal review of the FDA's Feb. 14 decision to invoke an application integrity policy (AIP) for the firm's submissions
You may also be interested in...
Regulatory News In Brief
CoA guidance: CDRH draft guidance on condition-of-approval study reports clears FDA's Office of Chief Counsel vetting process and should be released shortly, according to an Office of Surveillance and Biometrics staffer. Responsibility for tracking and reviewing CoA studies was transferred to OSB from the Office of Device Evaluation in January (1"The Gray Sheet, April 11, 2005, p. 8)...
Regulatory News In Brief
CoA guidance: CDRH draft guidance on condition-of-approval study reports clears FDA's Office of Chief Counsel vetting process and should be released shortly, according to an Office of Surveillance and Biometrics staffer. Responsibility for tracking and reviewing CoA studies was transferred to OSB from the Office of Device Evaluation in January (1"The Gray Sheet, April 11, 2005, p. 8)...
Ankle Prosthetic Petition Opposed; Endotec Says AIP Corrective Actions OK’d
A long-pending FDL-1petition under FDA review to reclassify mobile-bearing total ankle replacement prostheses from Class III to Class II faces new opposition